105 results
Page 4 of 6
SC TO-T
EX-99
73kxf km7482vgqagr
13 Jan 12
Third party tender offer statement
12:00am
8-K
EX-99.1
vo7netx3npy7 ihv
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
8-K
EX-99.1
m8aq3ifs86jbsvu
28 Jul 11
Important Clinical Data and Strong Financial Results
12:00am
8-K
EX-99.1
94mey6t 83ml425
28 Apr 11
Key R&D Milestones and Strong Financials
12:00am
8-K
EX-99.1
ir9yh6u 8d9e08qi9ln
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
wzsrpgemny86 ukm3
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
8-K
EX-99.1
qnsmz896
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am
8-K
EX-99.1
0skhrt0jmt9d84wm0xbv
29 Apr 10
Bristol-Myers Squibb Reports Strong Sales, Earnings Performance in First Quarter
12:00am
8-K
EX-99.1
lkbu gq68uc
28 Jan 10
Strong Operational and Strategic Performance in Fourth Quarter Caps Transformative 2009
12:00am